Scalper1 News
The prescription-drugmaker group has slipped in recent weeks, falling below its 50-day moving average, as several high-profile earnings reports loom. IBD’s Medical-Ethical Drugs group has fallen to No. 20 out of 197 after being ranked No. 1 six weeks ago. The group is still up 25% this year, easily beating the S&P 500. Prescription-drug stocks have been buoyed by strong earnings reports and a flurry of acquisitions, many of which were motivated at Scalper1 News
Scalper1 News